Insights
Insights From Our Experts
Articles
CMS Adopts Automatic Medicare Coverage of Breakthrough Devices
The Centers for Medicare and Medicaid Services (CMS) on January 12 finalized its proposal of Medicare Coverage of Innovative Technology (MCIT), an additional pathway of coverage for breakthrough-designated medical devices, providing timelines and clarifying definitions of…
Emerging 2021 Life Science Priorities
From commercializing high-science therapies to empowering a data-driven patient experience (in the midst of a global pandemic!), we’ve learned that the life sciences industry requires agility, speed and scale. How will 2020 experiences set the emerging…
A Rundown of 2020 Trends in Pharma
As we begin 2021 and vaccines roll out across the globe, it seems that the world is hopeful and eager to move forward from 2020. The COVID-19 pandemic impacted almost every aspect of our lives, wreaking havoc on numerous industries and forcing global companies to re-evaluate their…
EVERSANA is Fighting COVID-19 Through a Growing Number of Client Engagements
The new year began with a light of hope ignited by the long-awaited COVID-19 vaccine. However, a vaccine is only the first step in fighting the pandemic. Healthcare professionals and drug manufacturers must continue to apply…
PharmaVOICE Digital Influencers: Brigham Hyde
Data Is Transforming the Landscape In a special feature on Digital Influencers, PharmaVOICE Editor Taren Grom sat down with Brigham Hyde, President, Data & Analytics to discuss how data is transforming the life sciences landscape as…
How to Enhance Provider and Patient Engagement in Tech-Savvy Healthcare
Pharmaceutical representatives have always been a welcomed resource and consistent office visitor for healthcare providers (HCPs). Today, in a world operating largely virtually, pharma reps are re-strategizing HCP engagement in the same way providers are rethinking…
High-Efficiency Commercialization for High-Science Brands
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…
Leading the Way in Digital Health With Tech-Driven Clinical Pathways
Digital health technologies have become integral to patient care since the beginning of the COVID-19 pandemic and will remain essential healthcare tools. As many patients and healthcare providers are embracing digital health devices, clinical pathway developers have…
Patient Empowerment on the Rise with Health Consumerism
There’s no question that the pharma industry is evolving, and so are company relationships with patients as health consumerism gains popularity. While the COVID-19 pandemic created an immediate need for telehealth options, patients are seeing their own personal needs for customized healthcare options overall. Today’s…
How Does the Biden Administration Want to ‘Take on Pharma?’
Throughout his campaign, Biden has promised to, once in office, expand access to health care through the “Biden Plan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,” while “taking on big pharma”…